Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Oliver Schoor"'
Autor:
Ignacio I Wistuba, Mamta Kalra, Linus Backert, Martin Wermke, Edwin R Parra, Jason John Luke, Apostolia M Tsimberidou, Sebastian Bunk, Mohammad B Hossain, Andrea Mayer-Mokler, Arun Satelli, Norbert Hilf, Steffen Walter, Cedrik M Britten, Van K Morris, Tobias A W Holderried, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Sandra Grund-Gröschke, Katrin Aslan, Anantha Marisetty, Swapna Satam, Jens Hukelmann, M Alper Kursunel, Karine Pozo, Andreas Acs, Melissa Baumeister, Claudia Wagner, Oliver Schoor, Ali S Mohamed, Delfi Krishna
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 7 (2024)
Rationale of the trial Although the use of engineered T cells in cancer immunotherapy has greatly advanced the treatment of hematological malignancies, reaching meaningful clinical responses in the treatment of solid tumors is still challenging. We i
Externí odkaz:
https://doaj.org/article/6a562891133f4ee084b42c34b2d77b3e
Autor:
Minying Zhang, Jens Fritsche, Jason Roszik, Leila J. Williams, Xinxin Peng, Yulun Chiu, Chih-Chiang Tsou, Franziska Hoffgaard, Valentina Goldfinger, Oliver Schoor, Amjad Talukder, Marie A. Forget, Cara Haymaker, Chantale Bernatchez, Leng Han, Yiu-Huen Tsang, Kathleen Kong, Xiaoyan Xu, Kenneth L. Scott, Harpreet Singh-Jasuja, Greg Lizee, Han Liang, Toni Weinschenk, Gordon B. Mills, Patrick Hwu
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-10 (2018)
RNA editing is a biological process that creates sequence variation. Here the authors show that peptides generated as a consequence of RNA editing are naturally presented by human leukocyte antigen (HLA) and serve as antigens to elicit anti-tumour im
Externí odkaz:
https://doaj.org/article/2e9bfb402d00408685976df0bcbc9b99
Autor:
Oliver Schoor, Toni Weinschenk, Jörg Hennenlotter, Stefan Corvin, Arnulf Stenzl, Hans-Georg Rammensee, Stefan Stevanović
Publikováno v:
BioTechniques, Vol 35, Iss 6, Pp 1192-1201 (2003)
Gene expression analysis by microarrays using small amounts of RNA is becoming more and more popular against the background of advances and increasing importance of small-sample acquisition methods like laser microdissection techniques. The quality o
Externí odkaz:
https://doaj.org/article/41899b51eee44635967b71fe552dbfe7
Autor:
Apostolia M. Tsimberidou, Kerstin Guenther, Borje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner, Anna Nowak, Katrin Aslan, Arun Satelli, Fabian Richter, Sabrina Kuttruff-Coqui, Oliver Schoor, Jens Fritsche, Zoe Coughlin, Ali S. Mohamed, Kerry Sieger, Becky Norris, Rita Ort, Jennifer Beck, Henry Hiep. Vo, Franziska Hoffgaard, Manuel Ruh, Linus Backert, Ignacio I. Wistuba, David Fuhrmann, Nuhad K. Ibrahim, Van Karlyle. Morris, Bryan K. Kee, Daniel M. Halperin, Graciela M. Nogueras-González, Partow Kebriaei, Elizabeth J. Shpall, David Vining, Patrick Hwu, Harpreet Singh-Jasuja, Carsten Reinhardt, Cedrik M. Britten, Norbert Hilf, Toni Weinschenk, Dominik Maurer, Steffen Walter
Publikováno v:
Cancer Immunology Research.
IMA101 is an actively personalized, multi-targeted adoptive cell therapy (ACT), whereby autologous T cells are directed against multiple novel defined peptide-HLA (pHLA) cancer targets. HLA-A*02:01-positive patients with relapsed/refractory solid tum
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d46977681ac8a5cbd10f04dd9e8a6e33
https://doi.org/10.1158/2326-6066.cir-22-0444
https://doi.org/10.1158/2326-6066.cir-22-0444
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Supplementary Table S1. TUMAPs contained in IMA950 and associated source antigens. Supplementary Table S2. Statistical analysis underlying the recruitment of 20 immune evaluable patients per cohort. Supplementary Table S3. Reasons for HLA-A*02 positi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35bb952ed2561cc6de3f0f7698d8e249
https://doi.org/10.1158/1078-0432.22468137.v1
https://doi.org/10.1158/1078-0432.22468137.v1
Autor:
Stefan Stevanović, Karin Klingel, Hans-Georg Rammensee, Arnulf Stenzl, Dorothee Wernet, Jörg Hennenlotter, Martina Sauter, Anna Missiou, Björn Krämer, Margret Müller, Florian Altenberend, Oliver Schoor, Gitsios Gitsioudis, Cécile Gouttefangeas, Maria-Dorothea Nastke, Jörn Dengjel
Purpose: To elicit a long-lasting antitumor immune response, CD8+ and CD4+ T cells should be activated. We attempted to isolate HLA-DR–presented peptides directly from dissected solid tumors, in particular from renal cell carcinoma, to identify MHC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e0b01e59e8f23cb28c1ad001fd8a392
https://doi.org/10.1158/1078-0432.c.6518763.v1
https://doi.org/10.1158/1078-0432.c.6518763.v1
Autor:
James W.A. Ritchie, Sarah E. Halford, Harpreet Singh-Jasuja, Oliver Schoor, Karen Hill, Jane Peters, Lesley McGuigan, Norbert Hilf, Sarah Kutscher, Juha Lindner, Willie Stewart, Alan Jackson, Sarah Jefferies, Catherine McBain, Christopher J. Twelves, Omar Al-Salihi, Allan James, Paul J. Mulholland, Sharon Peoples, Roy Rampling
Purpose: To perform a two-cohort, phase I safety and immunogenicity study of IMA950 in addition to standard chemoradiotherapy and adjuvant temozolomide in patients with newly diagnosed glioblastoma. IMA950 is a novel glioblastoma-specific therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24176b5389b980038b76490af7d1161f
https://doi.org/10.1158/1078-0432.c.6526851.v1
https://doi.org/10.1158/1078-0432.c.6526851.v1
Autor:
Stefan Stevanović, Karin Klingel, Hans-Georg Rammensee, Arnulf Stenzl, Dorothee Wernet, Jörg Hennenlotter, Martina Sauter, Anna Missiou, Björn Krämer, Margret Müller, Florian Altenberend, Oliver Schoor, Gitsios Gitsioudis, Cécile Gouttefangeas, Maria-Dorothea Nastke, Jörn Dengjel
Methods, Tables 1-3, Figures 1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24996d72af328527272d899f4675d81b
https://doi.org/10.1158/1078-0432.22441875
https://doi.org/10.1158/1078-0432.22441875
Autor:
Stefan Stevanović, Hans-Georg Rammensee, Thomas Joos, Dorothee Wernet, Oliver Schoor, Karin Klingel, Nicole Schneiderhan-Marra, Florian Altenberend, Dominik Maurer, Andreas O. Weinzierl
Supplementary Table 1 from A Cryptic Vascular Endothelial Growth Factor T-Cell Epitope: Identification and Characterization by Mass Spectrometry and T-Cell Assays
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::164e0f8c75ccf64986745488cc853d48
https://doi.org/10.1158/0008-5472.22373429
https://doi.org/10.1158/0008-5472.22373429
Autor:
Stefan Stevanović, Hans-Georg Rammensee, Thomas Joos, Dorothee Wernet, Oliver Schoor, Karin Klingel, Nicole Schneiderhan-Marra, Florian Altenberend, Dominik Maurer, Andreas O. Weinzierl
Vascular endothelial growth factor (VEGF) is involved in various physiologic processes, such as angiogenesis or wound healing, but is also crucial in pathologic events, such as tumor growth. Thus, clinical anti-VEGF treatments have been developed tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a90887287df13cd2d1708213a44c194c
https://doi.org/10.1158/0008-5472.c.6497072
https://doi.org/10.1158/0008-5472.c.6497072